

Mr A V Kaisary MA, ChM, FRCS

Consultant Urological Surgeon and Honorary Senior Lecturer
Department of Urology
The Royal Free hospital NHS Trust
The Royal Free and University College London Medical School

Personal details

Date of birth: 13th November 1945
Place of birth: Cairo
Nationality: British
Family: Married. Two sons: Philip James and Peter Alexander

Medical Education

1961 - 1967 University of Cairo
(Kasr El-Eini Medical School, Cairo)

Qualifications and Higher Degrees

June 1967 M.B., B.Ch. University of Cairo.
October 1970 Diploma in General Surgery. University of Cairo.
November 1975 FRCS. Royal College of Surgeons of England.
October 1984 Master of Arts status (MA). University of Oxford.
June 1987 ChM, thesis. University of Bristol.
“Drugs phenotypes in carcinoma of the bladder ”

Previous Appointments

01.09.67 - 31.08.68	Pre-registration, Cairo University Hospital, Cairo	
01.09.68 - 30.04.69	Medical Officer Rural Health Unit, Suez	General Surgery and Medicine
01.05.69 - 31.10.70	Senior House Officer Anglo-American Hospital, Cairo	General Surgery and Urology Prof H Grace
01.11.7. - 31.10.72	Registrar Anglo-American Hospital, Cairo	General Surgery and Urology Prof H Grace
01.11.72 - 31.10.73	Registrar	General Surgery

	Cairo University Hospital, Cairo	and Urology Prof M A Rifaat
28.02.74 - 31.08.74	Senior House Officer Royal Marsden Hospital London SW3	Urology Mr Grant Williams Mr W F Hendry Mr H J G Bloom
01.09.74 - 28.02.75	Senior House Officer Queen Mary's Hospital Roehampton, London SW15	A & E Department Mr P Aicroth
01.03.75 - 28.02.77	Registrar Royal London Homeopathic Staunton Hospital Ramsey London W1	General Surgery Mr M D M Mr G Mr D Churchill- Davidson
01.05.77 - 28.02.78	Resident Surgical Officer Fitzroy Nuffield Hospital London	General Surgery, Vascular and Urology
01.03.78 - 03.04.80	Middle Grade Registrar Charing Cross Hospital London W6	Urology Mr P F Philip
15.05.80 - 31.07.82	Senior Registrar Charing Cross Hospital & King Edward VII Hospital Windsor, Berks	General Surgery Mr J H Pendower Mr K W Reynolds Mr R J Luck
20.09.82 - 18.03.83	Senior Registrar Charing Cross Hospital London W6	General Surgery Mr J H Pendower Mr K W Reynolds
25.04.83 - 30.09.84	Clinical Research Fellow and Tutor in Urology Bristol Royal Infirmary Bristol	Mr J B M Roberts Mr P J B Smith
01.10.84 - 06.06.87	Clinical Lecturer in Urology and Renal Transplantation Nuffield Department of Surgery	Mr J C Smith Mr G J Fellows Professor P Morris

John Radcliffe Hospital
Oxford

Other appointments and affiliations

Membership of professional bodies and learned societies

Egyptian Medical Association (1967)
British Medical Association (1974)
Royal College of Surgeons of England (1975)
Christian Medical Fellowship (1974)
International Continence Society (1975)
British Association of Urological Surgeons (1978)
European Association of Urology (1980)
British Prostate Group (1981)
American Urological Association (1981)
American Basic Research Society (1994)

Administration

- The Royal Free Hospital NHS Trust:

Chairman of Sub-Committee of Medical and Scientific Equipment
(1988-1992)

Chairman of the wound Management Committee
(1993-1999)

Vice Chairman of the Nephrology - Urology Group - Lawn Road Division
(1995-1997)

Chairman of the Nephrology - Urology Group - Lawn road Division
(1997- 2000)

- Region:

Secretary to N.E Thames Region for Urological Advisory Committee
(1991- 1995)

Research Co-Ordinator, North Thames Urology Training Section
(1997- 2000)

- National:

Member of Cancer Bladder Subgroup, Medical Research Council
(1989- 1995)

Member of the Council of The Urology Section, The Royal society of Medicine
(1998- 1999)

Elected member to the Executive Council - Section of Oncology
British Association of Urological Surgeons
(2001- to date)

- International:

Principal investigator of the International Casodex Research Group
(1990- 1999)

Collaborative Scientist Researcher with Department of Oncology at The Mount
Sinai School of Medicine, New York, USA.
(1996 – to date)

- University:

MB BS Final Year Examiner in Surgery (University of London).

Selected examiner for Thesis submitted for Higher Degrees in Urology
(Ph D, M D and MS)

Member of the University Representative Group for Consultant appointments in
Urology.

Editorship:

Invited regular reviewer for manuscripts presented for publication to British Journal
of Urology and European Urology journals particularly in the field of Prostate
disease.

Prizes and Awards

Certificate of Excellence in Anatomy, University of Cairo (May 1964)

Master of Arts status (MA), University of Oxford (October 1984)

Visiting Professor, Department of Urology, Downstate Medical Center State.
University of New York (October 1984)

Prize for the best clinical work presented:

Alcohol consumption and smoking as risk factors in Urothelial Carcinoma
(A poster presentation)

VIIth Congress of the European Association of Urology.
Budapest, Hungary (June 1986)

Academic supervision

Frank CHINEGWUNDOH

Research Fellow in Urology (Sept 1990 - Sept 1992)

Drug phenotypes in bladder cancer

Paul RICHMOND

Research Fellow in Urology (Oct 1992 - 1995)

Chromosomal changes in prostate cancer and its clinical impact on management of the disease

Sarbjinder SANDHU

Research Fellow in Urology (Sept 1995 - July 1997)

To investigate the relationship between prostatic intraepithelial neoplasia and prostate cancer

Roy McGREGOR

Research Fellow in Urology (February 1998 - October 1999)

Molecular and Antibody staging of Prostate Cancer

Leye AJAI

Research Fellow in Urology (June 1998 - October 1999)

Investigation of Chromosome pTEN Loss in Relation to Progression of Prostate Cancer

Ross Knight

Research Fellow in Urology (October 1999 - December 2001)

The effect of Growth Factors on Angiogenesis of Prostate adenocarcinoma

Farouk Khan

Research Fellow in Urology (December 2001 – October 2003)

Anatomical arrangement and phenotype of the nerves responsible for erectile function with reference to the human prostate gland

Teaching activity

I am a teacher to undergraduate medical students of the joint RFH and UCH medical school and participate in post-graduate teaching seminars for local and national general practitioners. Several attachments to post graduate Urology trainees have been made where Oncological urological training was offered to post-graduate candidates from abroad including Moscow, Republic of China, Greece and Egypt. Candidates return home to Faculty and Specialised Oncological Units positions. I was awarded visiting Professorship to Downstate Medical Centre, State University of New York in 1984. I was invited as an Attending Professor to the Urological Association of the Republic of China in 1995. I am an invited lecturer in Urological Oncology by the European School of Oncology.

Enabling activity

At the time of my appointment to the Royal Free Hospital I followed Mr John Hopewell who was a General Surgeon with interest in Urology and Renal transplant. I was instrumental with the full help and support of the then Head of Department of Surgery, Professor Ken Hobbs to start building Urology as a separate specialty and a complement of urology trainees was created.

Collaboration with other departments allowed initiation of urological developments. Links with Dr Robert Dick, then the Head of Radiology, facilitated initiation of Minimally invasive Urology techniques. Female Urology link was developed with the department of Gynaecology with the support of the head of the unit, then Professor Robert Shaw.

My interest in Oncological Urology lead to the creation of “The prostate laboratory”. It was launched in 1988 aiming to provide the most up-to-date and advanced approach to diagnosis and management of prostate disease. The laboratory has facilities for ultrasound examination of the prostate gland and biopsy techniques on an outpatient basis under local anaesthesia. It also had the only microwave thermotherapy machine, which provided both transrectal and transurethral treatment of prostatic hypertrophy under local anaesthesia with no need for patient admission. It provided treatment for the difficult problem of prostatitis and quickly attracted patient’s referral from the whole country. The laboratory has been funded entirely through funds raised from my clinical research activities and charitable bodies. With the support of my colleagues in the department of Pathology, a collaborative team in Prostate pathology was born.

Introduction of Brachytherapy treatment of localised prostate cancer is the latest addition

to the Lab activities. It is a relatively new treatment modality, which is gaining popularity worldwide. I initiated this modality at The Royal Free Hospital in 1999 and made it available to my Radiotherapy colleagues. In collaboration with Dr Katharine Pigott, Consultant Radiotherapist, the unit is the only one in the UK currently to offer treatment in a live single session mode as a day case attendance. An achievement I am proud of.

Research activity

It has always been my dream to engage in Urological research activity as a practicing clinician. My interest in bladder cancer, which was the basis for my higher degree project, led to my collaboration with Dr Alvaro Morales in Kingston, Canada in the late 70's. Intra-vesical BCG therapy was then a novel idea and I am proud to have been able to popularize this treatment modality in UK. This is the first choice intra-vesical therapy in superficial bladder cancer.

As the major contributor in prostate cancer trials programs during my training career, I became the Principal investigator in Luteinizing Hormone-Release Hormone (LH-RH) therapy and Anti-androgens clinical trials in UK. The "Prostate laboratory" at the Royal Free Hospital and Medical School became the leading Prostate cancer clinical trials unit in the country. The research program included clinical and laboratory projects as detailed in the clinical fellows section. Research collaboration with local regional centers include the Institute of Urology and the Academic department of Histopathology at UCL medical school. Internationally, a major collaborative link is established with the Oncology department at Mount Sinai Medical School in New York, USA and the Academic Department of Urology at the University of Vienna, Austria.

My aim is to expand and consolidate the current basic and clinical research activities and develop my already extensive collaborations, nationally and internationally in the field of prostate cancer. My goal is to achieve more and better understanding of this disease in an attempt to improve the outcome of its treatment in the male patient.

Publications

Books

1. Drug phenotypes in carcinoma of the bladder
Kaisary AV
University of Bristol, ChM. Thesis: 1987
2. A Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment.
Kaisary AV, Murphy GP, Denis L, Griffiths K., Editors.
London: Martin Dunitz Ltd, 1999.

Chapters in books

1. Bacillus Calmette-Guerin (BCG) treatment of superficial bladder tumours.
Kaisary A V
Recent Advances in Urology/Andrology (5)
Edited by W F Hendry.
Churchill Livingstone, 1991. pp 119- 134.
2. Prostate Cancer: Past, Present and Future
Kaisary AV
Curent Therapy for Prostate Cancer. Ed. Kotake, Shimazaki, Aso and Denis.
Excerpta Medica 1992. pp 131-139
3. Antiandrogens.
Furr BJA, Kaisary AV.
In Kaisary AV, Murphy GP, Denis L, Griffiths K, Editors.
Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment.
Martin Dunitz, London, England, UK 1999. pp 277-290.
4. LH-RH Agonist role in prostate cancer management.
Kaisary AV
In: Hormone Therapy in Breast and Prostate Cancer.
Editors: Craig Jordan V and Furr BJA
Humana Press, Totowa, New Jersey, USA, 2002. Chapter 17 pp 369 - 382.
5. The scientific evidence and expert opinion based on surgical intervention in prostate cancer.
Kaisary AV, Knight R and Jarmulowicz M.
In: The Effective Management of Prostate cancer.
Editors: Wallace DMA, Oliver RTD, Ash D and Miles A.
The Key Advances Series 2002. Chapter 5 pp 75 - 82.

Refereed articles

1. A temporary biological dressing in the treatment of varicose ulcers and skin defects.
Kaisary AV
Postgraduate Medical Journal, 1977; 53: 672-673.
2. Beehive on the bladder - sign of colovesical fistula
Kaisary and Grant RW
Annals of the Royal College of Surgeons of England, 1981; 63: 195-197.
3. A study of Cefamandole prostatic tissue levels
Kaisary AV
British Journal of Urology, 1981; 53: 336-338.
4. A case of bilateral intra-abdominal testes and seminoma in a previously unrecognised hermaphrodite.
Kaisary AV and Grant Williams
British Journal of Urology, 1981; 54: 323.
5. Management of unintentional distal embolisation following intravascular occlusive therapy
Kaisary AV, McIvor J and Grant Williams
British Journal of Surgery, 1982; 69: 422.
6. Is there a place for urodynamics in the assessment of stress urinary incontinence in females?
Kaisary AV
Proceedings of the 2nd Joint Meeting of the International Continence Society and the Urodynamic Society, 1983, Aachen, West Germany, pp. 457-458
7. Beta-ganglion blockade of female bladder function
Kaisary AV
Proceedings of the 2nd Joint Meeting of the International Continence Society and the Urodynamics Society, 1983, Aachen, West Germany, pp. 530-531
8. Intravesical prostaglandin therapy for atonic bladder.
Kaisary AV and Philip PF
Proceedings of the 2nd Joint Meeting of the International Continence Society and the Urodynamics Society, 1983, Aachen, West Germany, pp. 538-539

9. Urethral tonus and the levator sling - a study of 7 patients post-rectopexy.
Kaisary AV
Proceedings of the 2nd Joint Meeting of the International Continence Society and the Urodynamics Society, 1983, Aachen, West Germany, pp. 474-475
10. Urethral pressures before and after surgery for incontinence - a comparison of results of anterior vaginal repair versus colposuspension
Kaisary AV
Proceedings of the 2nd Joint Meeting of the International Continence Society and the Urodynamics Society, 1983, Aachen, West Germany, pp. 349-350
11. Long-term results of optical urethrotomy.
Smith PJB, Roberts JBM, Ball AJ and Kaisary AV
British Journal of Urology, 1983; 55: 698-700.
12. Tumour infarction after pre-operative embolisation of renal carcinoma.
McIvor J, Kaisary AV, Grant Williams and Grant RW
Clinical Radiology, 1984; 35: 59-64.
13. Late results of optical urethrotomy
Smith PJB, Kaisary AV and Ball AJ
Journal of the Royal Society of Medicine, 1984; 77: 105-107.
14. The role of The Beehive Cystogram in the diagnosis of colovesical disease.
Kaisary AV
British Journal of Urology, 1984; 56: 35-37.
15. The use of collagen implant for posterior rectopexy in complete rectal prolapse: Preliminary communications.
Kaisary AV, Luck RJ and Pendower JEH
Journal of the Royal Society of Medicine, 1984; 77: 201-203
16. Disorders of the external genitalia in the male
Smith PJB and Kaisary AV
The Practitioner, 1984; 228: 733-741
17. Beta-adrenoceptor blockade in the treatment of female urinary incontinence
Kaisary AV
Journal de Urologie, 1984; 90 (5): 351-353
18. Role of pre-operative embolisation in renal cell carcinoma
Kaisary AV, Grant Williams and Riddle PR
Urology Digest, 1985: 9

19. Spinal cord ischaemia after ligation of both internal iliac arteries during radical cystoprostatectomy
Kaisary AV and Smith PJB
Urology, 1985; 25 (4): 395-397
20. The incorporation of ⁷⁵Se by renal carcinoma cells exposed to cytotoxic agents: a possible test for drug sensitivity
Kaisary AV, Heinemann D, Smith PJB and Symes MO
British Journal of Surgery, 1985; 72 (5): 409-410
21. Primary localised Amyloidosis of the urethra
Kaisary AV
European Urology, 1985; 11 (3): 209
22. Is a single collection of 24 hours excretion reliable and reproducible?
Kaisary AV and Smith PJB
Indian Journal of Urology, 1985; 2 (1): 11-14
23. Post-operative care following internal urethrotomy
Kaisary AV
Urology, 1985; 26 (4): 333-336
24. Urachal abscess remnant in an adult
Kaisary AV
Journal of de Urologie, 1985; 91 (8): 523-524
25. Prazosin, priapism and management
Kaisary AV and Smith PJB
British Journal of Urology, 1986; 58 (2): 227-228
26. Assessment of radiotherapy in invasive bladder carcinoma using in-vivo methylene blue staining technique
Kaisary AV
Urology, 1986; 28 (2): 100-102
27. Aetiological factors and management of priopism in Bristol (1978-1983)
Kaisary AV and Smith PJB
The Annals of the Royal College of Surgeons of England, 1986' 68: 252-254
28. Post-operative care following internal urethrotomy
Kaisary AV
The Year Book of Urology 1986
Edited by J Y Gillenwater and S S Howards,
Year Book Medical Publishers, Inc. Chicago, London. Pp. 255-256

29. Intravesical BCG therapy in the management of multiple superficial bladder carcinoma: comparison between Glaxo and Pasteur strains.
Kaisary AV
British Journal of Urology, 1987; 59: 554-558

30. Genetic predisposition to bladder cancer: Ability to hydroxylate Debrisoquine and Mephenytoin as risk factors.
Kaisary AV, Smith PJB, Jaczq E, McAllister CB, Wilkinson GR, Ray WA and Branch RA
Cancer Research, 1987; 47: 5488-5493

31. A prospective randomised multi-centre study of surgical orchidectomy versus LHRH agonist AZoladex (ICI 118, 630) in management of metastatic prostatic carcinoma
Kaisary AV, Ryan RG, Turkes A, Peeling WB and Griffiths K
Progress in Clinical and Biological Research (Vol 260), 1988
Management of Advanced Cancer of Prostate and Bladder
Edited by P A Smith, Publishers A R Liss, Inc. - New York. Pp. 89-100

32. Multiple unilateral renal angiomyolipomas with regional lymphangiomyomatosis.
McIntosh GS, Dutoit SH, Chronos NV and Kaisary AV
The Journal of Urology, 1989; 142: 1305-1307

33. Testing the chemosensitivity of renal carcinoma in vitro
Lai T, Ferro MA, Kaisary AV, Smith PJB and Symes MO
British Journal of Urology, 1989; 64: 25-29

34. Prostatic Cancer - New Approaches to Endocrine Therapy
Smith PH, Hoisaeter P, Lunglmayr G, Iversen P, Crawford ED, Neri R, Milsted R, Kaisary AV, Fourcade RO, Newling DWW, Boccardo F, Furr BJA, Disilverio F.
Proceedings of a Symposium held at The 9th Congress of The European Association of Urology Amsterdam, The Netherlands, 13-16, 1990.
Round-Table Discussion.
European Urology 1990; 18 (Suppl.3): 62-66.

35. Intravesical BCG therapy for superficial bladder cancer long-term review.
Persad R, Kaisary A, Mukherjee A, Smith PJB.
Fifth Scientific Meeting of the BOA (British Oncological Association), London, England, UK, July 2-4, 1990.
British Journal of Cancer 1990; 62(Suppl.11): 21.

36. Comparison of LHRH analogue (Zoladex) with orchidectomy in patients with metastatic prostatic carcinoma.
Kaisary A V, Tyrrell C J, Peeling W B , Griffiths K
British Journal of Urology, 1991; 67: 502-508

37. Percutaneous renal tumour resection.
Gleeson F V, Dick R, Kaisary A V
Journal of Interventional Radiology (1991) 6, 131-132

38. Comparison of LHRH analogue (Zoladex) with orchidectomy in patients with metastatic prostatic carcinoma.
Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. [published erratum appears in Br J Urol 1993 May; 71(5): 632].
British Journal of Urology 1991; 67(5): 502-508.

39. Recurrence of bladder cancer is associated with cytochrome P450IID6 debrisoquine 4-hydroxylase activity.
Fleming CM, Kaisary AV, Wilkinson GR, Smith P, Branch RA, Persad R
Sixth Scientific Meeting of the British Oncological Association,
Bath, England, UK, June 30-July 2, 1991
British Journal of Cancer 1991; 64(Suppl. 15):22.

40. Angiomyolipoma of the kidney: a clinical enigma in diagnosis and management.
Wong K, Water CM, Hershman MJ, Kaisary AV and J Horner
Annals of the Royal College of Surgeons of England. March 1992; 74: 144 -148.

41. Debrisoquine metabolism status as a risk factor for bladder cancer.
Kaisary AV ,Chinegwundah FI, Gough AC, Smith DCA, Wolf RC and Spurr NK
Urology 1992, Edited by Luciano Guliani and Paolo Puppo
Bologna, 1992, pp 383-386

42. “Casodex” an acceptable monotherapy for advanced prostate cancer?
Preliminary results of a randomised trial against castration
Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F
Urology 1992, Edited by Luciano Guliani and Paolo Puppo,
Bologna, 1992, pp 587-590.

43. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled study
Lloyd SN, Buckley JF, Chilton CP, Ibrahim I, Kaisary AV and Kirk D
British Journal of Urology, November 1992; 70 (supp; 1): 17-21

44. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
Bunce C, Kaisary AV.
British Journal of Urology 1992; 69(4): 441-442.
45. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer.
Fleming CM, Kaisary AV, Wilkinson GR, Smith P, Branch RA.
Pharmacogenetics 1992; 2(3): 128-134.
46. Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer.
Fleming CM, Persad R, Kaisary AV, Smith P, Adedoyin A, Porter J, Wilkinson GR, Branch RA.
Pharmacogenetics 1994; 4(4): 199-207.
47. Current clinical studies with a new nonsteroidal anti-androgen, Casodex.
Kaisary AV
Prostate - Supplement 1994; 5:27-33.
48. A comparison of intramuscular ketorolac and pethidine in the alleviation of renal colic.
Sandhu DPS, Iacovou JW, Fletcher MS, Kaisary AV, Philips NH and Arkell DG
British Journal of Urology (1994), 74: 690-693.
49. Pre-operative embolisation in renal cell carcinoma
Kaisary AV, Grant Williams and Riddle PR
The Journal of Urology, April 1994; 131: 641-646.
50. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation.
Gingell JC, Knonagel H, Kurth KH, Tunn UW, Ackermann R, Funke PJ, Guddat HM, Nagel R, Jacobi GH, Senge T, Barthsch G, Kaisary AV, Hauri D and Schroder FH
Journal of Urology, 1995; 154: 399-401.
51. A randomised comparison of monotherapy with Casodex 50mg daily and castration in the treatment of metastatic prostate carcinoma
Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F and the Casodex Study Group.
European Urology, 1995; 28: 215-222.

52. Bone scintigraphy as a predictor of outcome in carcinoma of the prostate.
Buscombe JR, Richmond PJM, Kaisary AV.
Journal of Nuclear Medicine 1995; 36(5 Suppl.): 196P.
53. Obturator herniation following radical cystoprostatectomy.
Austin RCT, Kaisary AV and Winslet MC.
British Journal of Urology, 1995; 76(6): 800.
54. Measurement of prostate specific antigen as screening test for prostate cancer.
Trials of treatment are needed before trials of screening [letter; comment].
Sandhu S, Morris R, Matveev V, Kaisary AV.
British Medical Journal, 1996; 312(7032): 709-710.
55. Absence of Hepatic Enzyme Induction in Prostate Cancer Patient Receiving
Casodex (Bicalutamide)
Kaisary AV, Klarskov P, McKillop D
Anti-Cancer Drugs, 1996; 7 (1): 54 - 59.
56. Polymorphism and smoking in bladder carcinogenesis.
Chinegwundoh FI, Kaisary AV
British Journal of Urology, 1996; 77 (5): 672 - 675.
57. Compliance with hormonal treatment for prostate cancer. [Review].
Kaisary AV
British Journal of Hospital Medicine 1996; 55(6): 359-366.
58. Measurement of prostate specific antigen as screening test for prostate cancer.
Warren P, Neal DE, Hamdy FC, Sandhu S, Morris R, Matveev V, Kaisary AV,
Bartlett WA, Jones AF, Murphy P, George L, Watt HC, Kirby R, Knekt P,
Helzlsour KJ and Tuomilehto J.
British Medical Journal, 1996; 312(7032): 708-710.
59. The Extent of Disease on the Initial Isotope Bone Scan - An Indicator of Survival
in Prostate Cancer Patients.
Richmond PJM, Buscombe JR, Hilson AJW, Kaisary AV
Radionuclutides in Nephrology. Edited by Andrew Taylor, Joseph V Nally,
Henrik Thomsen, Published by Society of Nuclear Medicine, Inc, Reston, VA
20190-5316.1997, p 211-215.
60. Localised carcinoma of the prostate: a paradigm of uncertainty
Sandhu SS, Kaisary AV
Postgraduate Medical Journal, 1997, 73, No. 865: 691-696.

61. Pure small cell carcinoma of the prostate
Sandhu SS, Denton A, Jarmulowicz M, Pigott K and Kaisary AV
Clinical Oncology, 1997; 9: 412-414.
62. Familial Prostate Cancer Study: The evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study.
Eeles RA, Dearnaley DP, Ardern-Jones A et al.
British Journal of Urology - Supplement.1997; 79 (1): 8-14.
63. A prospective randomized study comparing a catheter-valve with a standard drainage system.
Wilson C, Sandhu SS and Kaisary AV
British Journal of Urology, 1997; 80: 915-917.
64. Aberrant E-cadherin and alpha-catenin expression in prostate cancer correlation with patient survival.
Richmond PJM, Karayiannakis AJ, Nagafuchi A, Kaisary AV and Pignatelli M
Cancer Research, 1997; 57(15): 3189-3193.65.
65. Antiandrogen monotherapy in the management of advanced prostate cancer.
Kaisary AV
European Urology.1997, 31 Suppl 2:14 -19; discussion 24-27
66. Finasteride plus Flutamide for prostatic carcinoma.
Sandhu SS, Matveev VB, Kaisary AV
British Journal of Urology, 1997; 80:360.
67. Radical Prostatectomy from three centres in the UK.
Sandhu SS, Kaisary AV, Matveev VB
British Journal of Urology, 1997, 80:189 - 190
68. New perspectives in the treatment of prostate cancer - Discussion.
Boccon-Gibod L, Crawford D, Scher HI, Fourcade RO, Tolis, Trachtenberg J, Schalken JA, Kaisary AV, Akdas A
European Urology 1997; 31(Suppl 2): 24-27.
69. Localised carcinoma of the prostate: a paradigm of uncertainty [Review].
Sandhu SS, Kaisary AV.
Postgraduate Medical Journal, 1997; 73 (865): 691-696.
70. The effect of LHRH agonists on prostatic intraepithelial neoplasia.
Jarmulowicz M, Sandhu SS, Walker T, Kaisary AV.
Journal of Pathology 1998; 184 (Suppl.): A13.

71. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G.
European Urology, 1998; 33 (5): 447-456.
72. Exploratory post-hoc survival evaluation in M1 prostate cancer patients treated with bicalutamide ('Casodex').
Kaisary AV, Iversen P, Tyrrell CJ, Anderson J, Van Poppel H, Tammela T, Chamberlain M.
Annals of Oncology 1998; 9 (Suppl. 4): 57.
73. Two 6-month sustained release depots of avorelin, a new LHRH agonist: Preliminary endocrinological and pharmacokinetic results in Prostate cancer patients.
Kaisary AV, Bowsher WG, Gillatt DA, Anderson JB, Malone PR, Cesana M.
Journal of Urology 1998; 159(5 Suppl.): 1299.
74. Prospects for improving survival in early prostate cancer: Results and ongoing studies with the non-steroidal anti-androgen bicalutamide (Casodex).
Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T and Chamberlain M.
Journal of Urology, 1998; 159(suppl.): 1031.
75. Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicentre randomised trials at a median follow up of 4 years.
Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K and Blackledge GRP.
Urology, 1998; 51(3): 389-396.
76. The effect of LHRH agonists on prostatic intraepithelial neoplasia.
Jarmulowicz M, Sandhu SS, Walker T and Kaisary AV.
Journal of Pathology, 1998; 184(suppl.): A13.
77. Pharmacodynamics of a long acting depot of Avorelin in patients with prostate cancer. Avorelin study group.
Kaisary AV, Bowsher WG, Gillatt DA, Anderson JB, Malone PR, Imbimbo BP
Journal of Urology 1999; 162 (6): 2019-2023

78. The clinical importance of the spatial association of PIN with cancer.
Knight R, Green JSA, Walker T, Jarmulowicz M, Simmonds N, Kaisary
Scandinavian Journal of Urology & Nephrology Supplementum 1999;
(200): 13-14.
79. Genetic predisposition to prostate cancer.
Eeles RA, Dearnaley DP, Arden-Jones A et al
Prostate Cancer and Prostatic Diseases, 1999; 2(1): 9-15.
80. Comparison of 'Casodex' (bicalutamide) 150 mg monotherapy with castration in
previously untreated non-metastatic prostate cancer: Mature survival results.
Iversen P, Tyrrell CJ, Anderson JB, Baert L, Chamberlain M, Kaisary AV,
Tammela T, Carroll K, Melezinek I.
European Urology 2000; 37(Suppl. 2): 128.
81. Patient - Clinician choice in palliation of metastatic prostate cancer.
Kaisary AV.
Drugs & Aging, 2000; 17(5): 331-337.
82. An investigation into the relationship between BPH and male erectile
dysfunction.
Green JSA, Holden STR, Bose P, St George DP, Kaisary AV, Bowsher WG.
European Urology 2000; 37(Suppl. 2): 3.
83. Comparison of 'Casodex' (bicalutamide) 150 mg monotherapy with castration in
previously untreated non-metastatic prostate cancer: Mature survival results.
Iversen P, Tyrrell CJ, Anderson JB, Baert L, Chamberlain M, Kaisary AV,
Tammela T, Carroll K, Melezinek I.
Journal of Urology 2000; 163 (4 Suppl.): 158.
84. The expression profile for the tumour suppressor gene PTEN and associated
polymorphic markers.
Hamilton JA, Stewart LMD, Ajayi L, Gray IC, Gray NE, Roberts KG, Watson
GJ, Kaisary AV, Snary D.
British Journal of Cancer 2000; 82(10): 1671-1676.
85. Palliative care options for advanced prostate cancer.
Kaisary AV and Knight R.
Oncology Spectrums 2001; 2(7): 462-468.
86. Is there a role for antiandrogen monotherapy in patients with metastatic prostate
cancer
Kaisary AV, Iversen p, Tyrrell cj, Carroll k and Morris t.
Prostate Cancer and Prostatic Disease 2001; 4: 196-203.

87. Bicalutamide. A view point.
Kaisary AV
Drugs 2002; 62(17): 2480-2481.
88. Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.
Amobi NI, Guillebaud J, Kaisary AV, Turner E and Smith IC.
British Journal of Pharmacology 2002; 136(1): 127-135.
89. Complex PSA and complex PSA indices in combination with artificial neural networks to predict the outcome of repeated prostate biopsies: results of the European prostate cancer detection study.
Djavan B, Zlotta A, Boccon G, Remzi A, Ravery V, Kaisary A, Dobronski P, Schulman C and Tinzl M.
European Urology Supplements 1(2002); pp 119.
90. Complexed prostate specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: Results of the prospective multicenter European trial.
Djavan B, Remzi N, Zlotta A R, Ravery V, Hammerer P, Reissigl A, Dobronski P, Kaisary A and Marberger M.
Urology 2002; 60 (4 supplement 1): 4-9.
91. Contractile actions of imidazoline alpha-adrenoceptor agonists and effects of non-competitive alpha 1- adrenoceptor antagonists in human vas deferens.
Amobi N, Guillebaud J, Kaisary AV, Lloyd-Davies RW, Turner E, Christopher I, Smith H.
European Journal of Pharmacology 2003; 462: 169–177.
92. Treatment of Balanitis Xerotica Obliterans with topical Tacrolimus.
Pandher B S, Rustin M H A, Kaisary A V.
The Journal of Urology 2003; 170: 923.
93. Adjuvant Luteinising Hormone –Releasing Hormone (LHRH)-Agonist therapy in prostate cancer.
Kaisary A V and Jarmulowicz M.
UroOncology 2003; 3(2): 51 – 62.

94. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multi-centre audit.
Winkler M H, Khan F A, Hoh I M, Okeke A A, Sugiono M, McInerney P, Persad R, Kaisary A V, Gillat D A.
BJU International 2004; 93: 725 – 729.
95. In vitro deregulation of markers characteristic of human prostate epithelial cells.
Islam T A, Patel A, Kaisary A V, Mondragon A, Waxman J , Kamalati T.
Tissue & Cell 2004; 36: 107 – 113.

Other publications

1. Hydroxylation in patients with transitional cell carcinoma of the bladder
Kaisary AV, Smith PJB, Branch RA, McAllister B and Roy WA
The Journal of Urology, 1986; 135: 127A
2. Management of metastatic carcinoma of the prostate using LHRH analogue therapy.
Kaisary AV, Fellows GJ and Smith JC
The Journal of Urology, 1986; 135: 340A
3. Latex allergy in urological practice: Implications and precautions.
Sidwell RU, Green JSA, Kaisary AV.
Proceedings of 6th Mediterranean Congress of Urology.
In: El Demiry M, Editor
Bologna: Moduzzi Editore, 1999.
4. The correlation of systematic sextant biopsy with pathology
Green JSA, Hunter-Campbell JP, Sandhu SS, Kaisary AV.
The Sixth Mediterranean Congress of Urology, Cairo, Egypt, 1999.
5. Are the cancer detection rates in prostate screening studies purely a function of the population undergoing biopsy.
Green JSA, Hunter-Campbell JP, McGregor R, Kaisary AV.
The Sixth Mediterranean Congress of Urology, Cairo, Egypt ,1999.
6. Transvaginal Urethral Diverticulectomy [video].
Green JSA, Hunter-Cambell P, Sandhu SS, Kaisary AV.
British Association of Urological Surgeons Annual Meeting,1999.
7. Male Urethral Diverticulectomy [video].
Kaisary AV, Hunter-Campbell JP.
The Sixth Mediterranean Congress of Urology, Cairo, Egypt, 1999.

8. Prospective multicenter European study of complex PSA. CPSAD-TZ, CPSA-TZ, C/total PSA ratio, C/free PSA ratio, F/T PSA, PSAD and PSA-TZ for early prostate cancer detection in men with PSA levels B.
Djavan B, Zlotta A, Ravery V, Kaisary A, , Dobronski P, Reissigl A, Remzi M, Schulman C, Boccon G and Tinzl M.
European Urology Supplements 1(2002), pp 98.
9. Correlation of preoperative TRUS guided sextant biopsies with radical prostatectomy specimens.
Sandhu S, Walker T, St George D, Jarmulowicz M and Kaisary A V
European Urology Supplements 1(2002), pp 167.

Research trials program

<u>EPC Code</u>	<u>Approved</u>	<u>Title</u>
76/87	07/87	A multicentre study of comparative efficacy of oral Cyprotrone Acetate and Zoladex depot SC injections in management of locally advanced prostate carcinoma.
77/87	07/87	A multicentre study of comparative efficacy of oral Cyprotrone Acetate and Zoladex depot SC injections alone, and in combination in the treatment of metastatic prostatic carcinoma.
40/88	03/88	Investigation of Evans BCG in superficial bladder cancer.
119/88	02/89	BRPF & GFR in patients with urolithiasis and hypercalciuria.
18/89	04/89	A multicentre study of the safety & efficacy of Terazosin in the treatment of patients with benign prostatic hypertrophy.
35/90	04/90	Pain control in acute uteritic colic.
37/90	10/90	A randomised trial of primary chemotherapy in locally advanced bladder cancer.
51/90	05/90	An open multicentre study to compare the effect of orchidectomy & Casodex 5.0 in the treatment of advanced carcinoma of the prostate.
137/90	03/91	Randomised trial of Somaltuline versus Flutamide for the treatment of prostatic cancer escaping from primary therapy with medical or surgical castration.

138/90	02/91	The genetics of bladder cancer.
38/91	07/91	Placebo-controlled double-blind study to test the efficacy of the aromatase inhibitor Atamestane in patients with BPH not requiring surgical intervention.
39/91	07/91	An open study to assess liver enzyme induction in patients receiving Casodex (ICI 176 334) for the treatment of metastatic prostate cancer.
67/91	09/91	Multicentre placebo-controlled trial with Cernilton in BPH.
100/91	01/92	Intravesical irrigation in superficial bladder cancer followed by treatment with epocyl or Mitomycin-C at the time of first recurrence.
9/92	03/92	R85246 vs Cyproterone Acetate (CPA) in stage of prostate cancer patients in relapse first-line androgen ablation therapy: an international multicentre trial.
15/92	05/92	An evaluation of oral Cyprofloxacin as prophylaxis in urological surgery
143/92	12/92	Double-blind randomisation parallel group trial with Chlortenoxicam and Naproxen in patients with pain due to metastatic bone tumours
52/93	04/93	An evaluation of the pharmacokinetics and pharmacodynamics of Leuprorelin acetate TAP-144-SR (3m) in patients with clinical evidence of metastatic carcinoma of the prostate (stage T4).
56/93	04/93	A multicentre double-blind, safety and efficacy study of oral Levofloxacin in patients with complicated urinary tract infections
78/93	12/93	Comparative study of intravesical instillation of Epirubicin Bacillus Calmette Guérin or Bacillus Calmette Guerin + isoniazid in intermediate and high risk PTA-PT1 papillary carcinoma of the urinary bladder

13/94	07/94	Liarazol-Fumarate (R85246) vs placebo in the treatment of asymptomatic stage D ₂ prostate cancer patients with relapse of PS. An international multi-centre, double-blind, parallel group, dose finding trial
23/94	11/94	Study of Finasteride in association with either Flutamide or Zoladex as Acombination hormonal therapy@ for the clinical management of patients with stage M1 carcinoma of the prostate
36/94	23/94	Transurethral Microwave Therapy of benign hypertrophy of the prostate gland. To assess the safety and efficacy of transurethral thermotherapy of the prostate for treatment of benign hyperplasia
114/94	09/94	A phase II randomised, asymmetric, open, multi-centre study investigating the bioequivalence and pharmacokinetics of two different sustained release formulations of Triptorelin in patients with advanced prostate cancer
	09/94	A phase II, open, multi-centre, long-term, follow-up study of patients receiving Triptorelin as a 3 month preparation for the treatment of advanced prostate cancer
115/94	08/94	The effects of Alfuzosin in slow release formulation, on uroflowmetry, assessed by portable and conventional uroflowmetry and on pressure-flow relationships in patients with benign prostatic hyperplasia
149/94	11/94	A multi-centre, randomised and comparative to assess the tolerance (maximum well tolerated dose), efficacy and pharmacokinetics of escalating doses of casodex versus castration in the treatment of advanced carcinoma of the prostate.
168/94	10/94	Randomised trial of Epirubicin versus Mitomycin-C at the time of first recurrence in superficial bladder cancer
77/95	06/95	Comparative study of intravesical instillation of Mitomycin-C or Bacillus Calmette Guerin in recurrent superficial carcinoma of the urinary bladder
78/95	05/95	Randomised, double-blind, parallel group trial to compare the effects of Casodex (Zeneca AD 7054) (150mg OD) against Zoladex (3.6mg every 28 days) on sexual functioning in patients with locally advanced prostate cancer

98/95	06/95	A double-blind, double-dummy, randomised, multi-centre prospective clinical trial comparing the efficacy safety and cost effectiveness of a single dose of 500mg Ciprofloxacin to a single intravenous dose of 120mg Gentamicin in the prophylaxis of infection following urological surgery
128/95	08/95	A randomised, double-blind, parallel-group trial comparing Casodex 150mg daily with placebo in patients with non-metastatic prostate cancer
57/96	06/96	Investigation of the efficacy and safety of Liarozole in patients with hormone-refractory prostate cancer stage D ₂ (T ₀₋₄ N ₀₋₄ M ₁).
118/96	11/96	An open-label, dose-interval finding, randomised, phase III, multicentre study of the pharmacodynamics, pharmacokinetics, efficacy and tolerability of the new LHRH analogue Avorelin in patients with prostate cancer.
160/96	10/96	Multicentre, double-blind, placebo controlled, randomised, follow-up study of the efficacy and safety of an infusion of Ibandronate 2, 4 and 6mg given as required (maximum frequency every 2 weeks), for 6 months in patients with prostate cancer and bone metastases
161/96	11/96	Double-blind, placebo-controlled, randomised, multicentre study to evaluate the efficacy and safety of two i.v. infusions of 2, 4 and 6mg of Ibandronate on bone pain patients with prostate cancer and bone metastases
201/96	12/96	A multi-centre, randomised, double-blind, placebo-controlled trial to investigate the effect of Bicalutamide (Casodex TM) 150mg on the pharmacokinetics of Midazolam in prostate cancer patients
228/96	03/97	A prospective, controlled, randomised, double-blind, multinational study to evaluate the efficacy and safety of BAY12-8039 versus Ofloxacin for the treatment of community acquired complicated urinary tract infections
52/97	03/97	A phase II, double-blind, randomised trial to examine the effects and the tolerability of Liazal TM versus placebo with or without Vitamin E in patients with superficial bladder tumours.
11/98	03/98	Re: Casodex Study 176334/0307 -Bone Mineral Density Measurment.

31/98	04/98	A randomised, Double Blind, Double Dummy, Multicentre, Multi- National, Parallel-group, PhaseII/111Study comparing oral dose regimens of GC 5501 (200mg once daily Or once daily) and 500mg Ciprofloxacin given twice treatment of patients with complicated UTI.
two 400mg daily in the		
151/98	08/98	A phase II, randomised, open multicentre study in two parallel groups to assess the equivalence of Decapeptyl SR 3 month (test formulation) and Decapeptyl SR 28 day (Reference formulation), the efficacy and the tolerability Of Decapeptyl SR 3 month during the follow up period in patients with prostate cancer.
215/98	11/98	Dose ranging study comparing best medical therapy with and without ABT-627 for the treatment of men with asymptomatic hormone refractory adenocarcinoma of the prostate.
32/99	47/99	A multicentre, randomised, double -blind, double-dummy parallel-group study to compare the efficacy of G1198745 0.5 mg od versus Finestrade 5 mg od for 12 months in the treatment of subjects with benign prostate hyperplasia.
06/99	3790	A randomized trial of hormone therapy plus radical radiotherapy versus hormone therapy alone in non-metastatic prostate cancer.
radiotherapy prostate cancer.		
02/99	2183	Physiological mode of action of an autocrine/paracrine growth factor that is induced in skeletal muscle by physical activity.
09/99	3827	A multicentre randomized, double blind, parallel group, controled stydy to assess the effect of 100mg ZD6169 in subjects with idiopathic detrusor instability.
placebo- once daily		
11/99	3718	A phase III study of the use of a long term adjuvant hormonal treatment with LHRH analogue following a 6 months combined androgen blockade in locally advanced prostatic carcinoma by external irradiation.
treated		
11/99	3743	Phase III study of post-operative external radiotherapy in pathological stage T3 N0 M0 prostatic carcinoma.
08/00	13/00	Clinical trial to assess the efficacy and safety of a 3-month Leuprorelin acetate implant in patients with advanced

prostate cancer.

- | | | |
|-------|---------------------|---|
| 04/00 | 5033 | A phase III multicentre, double blind randomized, placebo controlled, parallel group study of Darifenacin vrs Tolterodine in patients with overactive bladder (urge urinary incontinence). |
| 05/00 | 4006 | A double-blind randomized, parallel group study with Alfuzosin 10mg od versus placebo in the return to successful voiding in patients with a first episode od acute urinary retention due to BPH. |
| 09/00 | 5226 | Open phase II study of the platinum analogue ZD0473 in patients with metastatic hormone refractory prostatic carcinoma. |
| 11/00 | 5167 | A multicentre prospective randomized study of the valiuue of a single dose of intravesical Mitomycin in preventing the development of bladder tumours following Nephro-ureterectomy for transitional cell carcinoma of the upper urinary tract. |
| 10/01 | 5650M | A phase III extension study to evaluate the safety and efficacy of 10mg Atrastane in men with hormone refractory prostate cancer (M00-258). |
| 11/01 | 5648M
of | A phase III randomized, double-blind, placebo controlled study of the safety and efficacy of 10mg Atrastane in men with non-metastatic hormone refractory prostate cancer (M00-211). |
| 12/01 | 5649M
metastatic | A phase III randomized, double-blind, placebo controlled study of the safety and efficacy of 10mg Atrastane in men with non-hormone refractory prostate cancer (M00-244). |
| 12/01 | 5696
for | Anatomical arrangement and phenotype of the nerves responsible for erectile function with reference to the human prostate gland. |
| 12/02 | 6053 | Tc 99m depreotide whole body scan in prostatic carcinoma. |
| 01/03 | 6078 | Survey to determine the prevalence of use of complementary and alternative therapies amongst patients with prostate cancer. |